Gilead, LEO Pharma Enter Strategic Partnership To Accelerate Development Of Oral STAT6 Program
Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule ...
Gilead, LEO Pharma partner to develop programs for inflammatory diseases
(Reuters) - Gilead Sciences (NASDAQ: GILD) said on Saturday that it entered into a partnership with Denmark's LEO Pharma to ...
Gilead in pact for anti-inflammatory drugs in a deal worth up to $1.7B
Gilead Sciences (GILD) partners with LEO Pharma in a $1.7B agreement to develop anti-inflammatory drugs. Read more here.
The American Journal of Managed Care12h
Student-Run Clinics Expand Access to Dermatology Care
For diverse patient populations who are historically marginalized within health care, student-run clinics may offer a ...
Pharmabiz13h
CAGE Bio begins phase 2b clinical trial for CGB-500, a breakthrough topical JAK inhibitor for moderate to severe atopic dermatitis
CAGE Bio begins phase 2b clinical trial for CGB-500, a breakthrough topical JAK inhibitor for moderate to severe atopic dermatitis: San Carlos, California Saturday, January 11, 20 ...
Managed Healthcare Executive23h
Mobility Issues are More Likely to Occur in Atopic Dermatitis Patients
Out of 6,540 patients involved in a study, 7.1% of those with AD had mobility impairment compared to 3.9% of those without AD ...